Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 7/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | EPOR | P19235 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16429306 | 0.86 | BCHE (0.44) | MEN1KMT2ASMN1; SMN2RAB9ABCHE | |
| SCHEMBL16264653 | 0.83 | BCHE (0.55) | MEN1KMT2ASMN1; SMN2RAB9ABCHE | |
| SCHEMBL16247106 | 0.83 | PNMT (0.37) | SIGMAR1 | |
| SCHEMBL16428817 | 0.82 | ERAP2 (0.35) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29778267 | 0.82 | BCHE (0.54) | MEN1KMT2ASMN1; SMN2RAB9ABCHE | |
| SCHEMBL6173498 | 0.82 | LTA4H (0.41) | MEN1KMT2ASMN1; SMN2RAB9ABCHE | |
| SCHEMBL16429081 | 0.82 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2RAB9ABCHE | |
| SCHEMBL16428993 | 0.81 | — | — | |
| SCHEMBL16246956 | 0.81 | CARM1 (0.38) | MEN1KMT2ASMN1; SMN2RAB9AKDM4E | |
| SCHEMBL16429451 | 0.80 | CNR1 (0.38) | KMT2AKDM4ESIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10440955-B2 | Methods comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180125070-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | THE UNIVERSITY OF UTAH | 2018-05-10 | — | — | US | disclosed |
| US-9839219-B2 | Compositions comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160330962-A1 | COMPOSITIONS COMPRISING A BIOCIDAL POLYAMINE | CURZA GLOBAL, LLC | 2016-11-17 | — | — | US | disclosed |
| US-9439433-B2 | Compositions and methods comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150038512-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | THE UNIVERSITY OF UTAH | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160330962-A1 | COMPOSITIONS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMS, SMOX | MEN1 1109/4885KMT2A 2137/4885SMN1; SMN2 4729/4885 |
| US-10440955-B2 | Methods comprising a biocidal polyamine | SRM, SMOX, SMS | MEN1 1586/4885KMT2A 2076/4885SMN1; SMN2 4734/4885 |
| US-20180125070-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMOX, SMS | MEN1 1222/4885KMT2A 1888/4885SMN1; SMN2 4731/4885 |
| US-20150038512-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMOX, SMS | MEN1 1222/4885KMT2A 1888/4885SMN1; SMN2 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.